JP2019507135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507135A5 JP2019507135A5 JP2018540141A JP2018540141A JP2019507135A5 JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5 JP 2018540141 A JP2018540141 A JP 2018540141A JP 2018540141 A JP2018540141 A JP 2018540141A JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding substance
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 239000000126 substance Substances 0.000 claims 15
- 230000008685 targeting Effects 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291774P | 2016-02-05 | 2016-02-05 | |
| US201662291772P | 2016-02-05 | 2016-02-05 | |
| US201662291769P | 2016-02-05 | 2016-02-05 | |
| US201662291779P | 2016-02-05 | 2016-02-05 | |
| US201662291776P | 2016-02-05 | 2016-02-05 | |
| US62/291,774 | 2016-02-05 | ||
| US62/291,779 | 2016-02-05 | ||
| US62/291,776 | 2016-02-05 | ||
| US62/291,772 | 2016-02-05 | ||
| US62/291,769 | 2016-02-05 | ||
| US201662335965P | 2016-05-13 | 2016-05-13 | |
| US201662335880P | 2016-05-13 | 2016-05-13 | |
| US201662336030P | 2016-05-13 | 2016-05-13 | |
| US201662335968P | 2016-05-13 | 2016-05-13 | |
| US201662335979P | 2016-05-13 | 2016-05-13 | |
| US62/336,030 | 2016-05-13 | ||
| US62/335,979 | 2016-05-13 | ||
| US62/335,968 | 2016-05-13 | ||
| US62/335,965 | 2016-05-13 | ||
| US62/335,880 | 2016-05-13 | ||
| US201662353607P | 2016-06-23 | 2016-06-23 | |
| US62/353,607 | 2016-06-23 | ||
| US201662411805P | 2016-10-24 | 2016-10-24 | |
| US62/411,805 | 2016-10-24 | ||
| PCT/EP2017/052553 WO2017134306A1 (en) | 2016-02-05 | 2017-02-06 | Cd8 binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507135A JP2019507135A (ja) | 2019-03-14 |
| JP2019507135A5 true JP2019507135A5 (enExample) | 2020-03-19 |
| JP6991979B2 JP6991979B2 (ja) | 2022-03-04 |
Family
ID=57995193
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
| JP2018540141A Active JP6991979B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｄ８結合物質 |
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US11001631B2 (enExample) |
| EP (8) | EP4059957A1 (enExample) |
| JP (7) | JP7166923B2 (enExample) |
| CN (9) | CN116769054A (enExample) |
| CA (4) | CA3013555A1 (enExample) |
| DK (3) | DK3411407T3 (enExample) |
| ES (3) | ES2981730T3 (enExample) |
| WO (4) | WO2017134301A1 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4059957A1 (en) * | 2016-02-05 | 2022-09-21 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| EP3648786A4 (en) | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES |
| WO2019028316A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
| US12091463B2 (en) * | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| WO2019032661A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
| CN111065649A (zh) * | 2017-08-16 | 2020-04-24 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| ES2941740T3 (es) | 2018-01-12 | 2023-05-25 | Amgen Inc | Anticuerpos anti-PD-1 y métodos de tratamiento |
| US12226481B2 (en) | 2018-01-24 | 2025-02-18 | Beijing Percans Oncology Co., Ltd. | Cytokine fusion proteins |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2019148089A1 (en) * | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CN118754990A (zh) * | 2018-02-05 | 2024-10-11 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| CN112512551A (zh) * | 2018-03-28 | 2021-03-16 | 奥里尼斯生物科学公司股份有限公司 | 双功能蛋白及其构建 |
| CN108727504B (zh) | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| MX2020011023A (es) * | 2018-04-19 | 2021-01-29 | Baylor College Medicine | Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1. |
| AU2019275737A1 (en) | 2018-06-01 | 2021-01-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| EP3802613A4 (en) * | 2018-06-05 | 2022-03-09 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | DIMER AND ITS USE |
| CA3107159A1 (en) * | 2018-07-24 | 2020-01-30 | Good T Cells, Inc. | Composition for preventing or treating immune-related diseases |
| CN112638415B (zh) * | 2018-07-26 | 2024-07-02 | 大有华夏生物医药集团有限公司 | 用于成像的组合物和方法 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| CN112585169A (zh) * | 2018-09-04 | 2021-03-30 | 南京优迈生物科技有限公司 | 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 |
| US12162947B2 (en) * | 2018-09-04 | 2024-12-10 | Nanjing Umab-Biopharma Co., Ltd. | Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection |
| CN120623346A (zh) * | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| WO2020097350A1 (en) * | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| US20220025050A1 (en) * | 2018-12-21 | 2022-01-27 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| US20230071889A1 (en) * | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| AU2020205965A1 (en) * | 2019-01-07 | 2021-07-01 | Shattuck Labs. Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| US12263234B2 (en) | 2019-01-23 | 2025-04-01 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-PD-L1 diabodies and the use thereof |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| EP3939610A4 (en) * | 2019-03-15 | 2023-01-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SMALL CELL LUNG CANCER |
| CN113840833B (zh) * | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| EP3946408A4 (en) * | 2019-03-28 | 2023-06-14 | Orionis Biosciences, Inc. | CHEMICAL PROTEINS AND CHEMICAL PROTEIN COMPLEXES AGAINST FMS-LIKE TYROSINE KINASE 3 (FLT3) |
| JP7689079B2 (ja) * | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| JP2022537515A (ja) * | 2019-06-10 | 2022-08-26 | アポロミクス インコーポレイテッド（ハンジョウ） | 抗体－インターロイキン融合タンパク質および使用方法 |
| US20220249609A1 (en) * | 2019-06-19 | 2022-08-11 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| CN118126195A (zh) * | 2019-08-30 | 2024-06-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
| MX2022002738A (es) * | 2019-09-04 | 2022-06-27 | Genentech Inc | Agentes de union a cd8 y uso de los mismos. |
| WO2021062181A1 (en) * | 2019-09-26 | 2021-04-01 | Orionis Biosciences, Inc. | Conjugated chimeric proteins |
| KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| WO2021110562A1 (en) | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| CN118562007A (zh) * | 2019-12-19 | 2024-08-30 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022002153A1 (zh) * | 2020-06-30 | 2022-01-06 | 正大天晴药业集团股份有限公司 | 用于治疗肿瘤的药物 |
| EP4178609A4 (en) * | 2020-07-07 | 2024-07-24 | Orionis Biosciences, Inc. | IMMUNOSTIMULATORY ADJUVANTS |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| CN116635052A (zh) * | 2020-10-13 | 2023-08-22 | 詹森生物科技公司 | 用于调节分化簇iv和/或viii的生物工程t细胞介导的免疫、材料和其他方法 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| WO2022111562A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| WO2022111618A1 (zh) * | 2020-11-26 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 |
| CN112724199B (zh) * | 2020-12-30 | 2023-01-24 | 郑州大学 | 亲和Clec9a的多肽及其应用 |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN115583995B (zh) * | 2022-01-30 | 2024-12-13 | 立凌生物制药(苏州)有限公司 | 双特异性抗体及其制备方法和应用 |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250171531A1 (en) * | 2022-02-10 | 2025-05-29 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN119584994A (zh) | 2022-05-02 | 2025-03-07 | 普雷西里克斯公司 | 预靶向 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| JP2024047762A (ja) | 2022-09-27 | 2024-04-08 | セイコーエプソン株式会社 | 成形用材料 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024145108A1 (en) * | 2022-12-28 | 2024-07-04 | Binacea Pharma, Inc. | Anti-cd8 antibodies and methods of use thereof |
| WO2024156881A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024269754A1 (en) * | 2023-05-08 | 2025-10-23 | F. Hoffmann-La Roche Ag | Targeted interferon alpha fusion proteins and methods of use |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119280420B (zh) * | 2024-10-14 | 2025-09-12 | 北京大学 | 多特异性偶联物及其应用 |
| CN120248112B (zh) * | 2025-06-04 | 2025-08-05 | 天津龙晟生物科技有限公司 | 一种叶酸单克隆抗体及其应用以及一种叶酸检测试剂盒 |
| CN120699170B (zh) * | 2025-08-22 | 2025-11-25 | 中生康元生物科技(北京)有限公司 | 一种三特异性单链抗体及其用途 |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| EP0294703B1 (en) | 1987-06-10 | 1995-05-10 | Dana-Farber Cancer Institute, Inc. | Bifunctional antibody constructs and method for selectively destroying cell populations |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DK0489116T3 (da) | 1989-08-22 | 1994-05-02 | Immunex Corp | Fusionsproteiner omfattende GM-CSF og IL-3 |
| EP0839536A1 (en) | 1989-10-27 | 1998-05-06 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| DK0786469T3 (da) | 1990-06-11 | 2006-07-10 | Gilead Sciences Inc | Nukleinsyreligander |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SE9201966D0 (sv) | 1992-06-25 | 1992-06-25 | Trion Forskning & Utveckling | Interleukin-1beta deletion mutant |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP1405911A1 (en) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| WO1997010338A1 (en) | 1995-09-12 | 1997-03-20 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
| ES2219679T3 (es) | 1995-10-18 | 2004-12-01 | Akzo Nobel N.V. | Vacuna de combinacion contra la enfermedad de newcastle. |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5986059A (en) | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK1144616T4 (da) | 1999-01-19 | 2009-03-30 | Unilever Nv | Fremgangsmåde til fremstilling af antistoffragmenter |
| ES2402878T3 (es) | 1999-05-05 | 2013-05-10 | Phylogica Limited | Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos |
| ES2371464T3 (es) | 1999-05-26 | 2012-01-03 | Next Biomed Technologies Nbt Oy | Métodos y materiales para generar dominios sh3 con propiedades de unión seleccionadas. |
| JP2001026545A (ja) | 1999-07-09 | 2001-01-30 | Takara Shuzo Co Ltd | 免疫応答活性化製剤 |
| NZ530583A (en) | 1999-08-23 | 2005-10-28 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US6613756B2 (en) | 2000-05-05 | 2003-09-02 | Wisconsin Alumni Research Foundation | Use of tetracycline derivatives in treating multiple sclerosis |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| GB0014356D0 (en) | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
| US20020025304A1 (en) | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| DE60142479D1 (de) | 2000-08-30 | 2010-08-12 | Penn State Res Found | Aminosäureaustauschmutanten von interleukin 13 |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| IL160289A0 (en) | 2001-08-30 | 2004-07-25 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| EP2444810A3 (en) | 2002-10-02 | 2013-01-02 | Catalyst Biosciences, Inc. | Proteases mutants with altered specificity and uses thereof |
| JP2006520584A (ja) | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| KR20050091713A (ko) | 2002-12-05 | 2005-09-15 | 프로테인 디자인 랩스 인코포레이티드 | 항-시디3 항체를 이용한 궤양성 대장염의 치료 방법 |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| EP1587907B1 (en) | 2003-01-07 | 2011-03-02 | Dyax Corporation | Kunitz domain library |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| TW201122103A (en) | 2004-01-06 | 2011-07-01 | Hayashibara Biochem Lab | Tnf antagonists and tnf inhibitors comprising the same as the active ingredient |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| JP2008507298A (ja) * | 2004-05-19 | 2008-03-13 | マキシジェン， インコーポレイテッド | インターフェロンαポリペプチドおよび結合体 |
| SG155883A1 (en) | 2004-06-03 | 2009-10-29 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| US7589314B2 (en) | 2004-07-12 | 2009-09-15 | Mitsubishi Denki Kabushiki Kaisha | Optical encoder applying substantially parallel light beams and three periodic optical elements |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| WO2006053883A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Fibronectin iii domain as leptin receptor antagonists |
| EP1827491A4 (en) | 2004-11-19 | 2010-07-14 | Biogen Idec Inc | TREATMENT OF MULTIPLE SCLEROSIS |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| EP2479191A3 (en) | 2005-05-18 | 2013-03-13 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
| KR101804078B1 (ko) * | 2005-06-08 | 2017-12-01 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| GB0513047D0 (en) | 2005-06-27 | 2005-08-03 | Thermo Finnigan Llc | Electronic ion trap |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2173377B1 (en) | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| CN108129573B (zh) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| DK2492355T3 (da) | 2007-11-29 | 2015-07-13 | Molecular Health Gmbh | Vævsbeskyttende erythropoietinreceptor (nepor) samt anvendelsesfremgangsmåder |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| CA2715166C (en) | 2008-02-11 | 2017-05-16 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよびその使用方法 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| CN102245623A (zh) | 2008-12-08 | 2011-11-16 | 康普里斯有限公司 | 单链反向平行卷曲型螺旋蛋白 |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| CN102361646A (zh) * | 2009-03-23 | 2012-02-22 | 沃尔特及伊莱萨霍尔医学研究院 | 调节免疫应答的化合物和方法 |
| KR20120053042A (ko) | 2009-08-17 | 2012-05-24 | 로슈 글리카트 아게 | 표적화된 면역접합체 |
| WO2011025904A1 (en) * | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| WO2011029870A1 (en) | 2009-09-10 | 2011-03-17 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| DK2504364T3 (da) | 2009-11-24 | 2017-11-06 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2577299C2 (ru) * | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| ES2579987T3 (es) | 2011-02-10 | 2016-08-18 | Roche Glycart Ag | Polipéptidos interleuquina-2 mutantes |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| SE535863C2 (sv) | 2011-07-18 | 2013-01-22 | Atlas Copco Ind Tech Ab | Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål |
| WO2013053008A2 (en) * | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| EA034989B1 (ru) * | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| EP2804877B1 (en) * | 2012-01-20 | 2018-08-22 | VIB vzw | Targeted mutant alpha-helical bundle cytokines |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US20150132302A1 (en) | 2012-05-01 | 2015-05-14 | The University Of Sydney | Vaccine and uses thereof |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2013186613A1 (en) | 2012-06-14 | 2013-12-19 | Nasvax Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| CN102775502A (zh) * | 2012-08-16 | 2012-11-14 | 天津禹王生物医药科技有限公司 | α干扰素融合蛋白 |
| CN105163765A (zh) * | 2013-03-13 | 2015-12-16 | 伊麦吉纳博公司 | 与cd8的抗原结合构建体 |
| EP2968535A2 (en) | 2013-03-15 | 2016-01-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Low concentration antibody formulations |
| AU2014286116A1 (en) | 2013-07-05 | 2016-02-04 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| CA2917937C (en) | 2013-07-18 | 2022-11-01 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
| SG11201600168UA (en) | 2013-07-19 | 2016-02-26 | Vib Vzw | Targeted modified tnf family members |
| US9732135B2 (en) | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| AU2014292377B2 (en) | 2013-07-19 | 2019-08-01 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted modified IL-1 family members |
| HUE057598T2 (hu) * | 2013-08-08 | 2022-05-28 | Cytune Pharma | IL-15 és IL-15R-alfa sushi domén alapú modulokinek |
| CN105848680A (zh) * | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| CA2953816C (en) * | 2014-06-30 | 2022-03-15 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| WO2016002263A1 (ja) | 2014-06-30 | 2016-01-07 | ソニー株式会社 | 無線通信装置、無線通信方法及びプログラム |
| JP6544775B2 (ja) | 2014-07-11 | 2019-07-17 | 株式会社ワコム | 位置指示器、位置検出装置、位置検出装置の入力制御方法および入力装置 |
| MX2017000857A (es) * | 2014-07-18 | 2017-10-11 | Advaxis Inc | Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata. |
| ES2987034T3 (es) | 2014-08-05 | 2024-11-13 | Apollomics Inc | Anticuerpos anti-PD-L1 |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| SG10202105879XA (en) | 2014-10-24 | 2021-07-29 | Astrazeneca Ab | Combination |
| JP6730271B2 (ja) | 2014-10-29 | 2020-07-29 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | インターフェロンα２Ｂバリアント |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) * | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP4059957A1 (en) * | 2016-02-05 | 2022-09-21 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
-
2017
- 2017-02-06 EP EP22160584.3A patent/EP4059957A1/en active Pending
- 2017-02-06 US US16/075,318 patent/US11001631B2/en active Active
- 2017-02-06 CN CN202310688728.7A patent/CN116769054A/zh active Pending
- 2017-02-06 EP EP21195070.4A patent/EP3998281A1/en active Pending
- 2017-02-06 EP EP17705564.7A patent/EP3411407B1/en active Active
- 2017-02-06 ES ES17704697T patent/ES2981730T3/es active Active
- 2017-02-06 DK DK17705564.7T patent/DK3411407T3/da active
- 2017-02-06 WO PCT/EP2017/052544 patent/WO2017134301A1/en not_active Ceased
- 2017-02-06 EP EP17703965.8A patent/EP3411065B1/en active Active
- 2017-02-06 CA CA3013555A patent/CA3013555A1/en active Pending
- 2017-02-06 CN CN202310688724.9A patent/CN117024599A/zh active Pending
- 2017-02-06 WO PCT/EP2017/052553 patent/WO2017134306A1/en not_active Ceased
- 2017-02-06 EP EP24168089.1A patent/EP4421094A3/en active Pending
- 2017-02-06 WO PCT/EP2017/052545 patent/WO2017134302A2/en not_active Ceased
- 2017-02-06 DK DK17704697.6T patent/DK3411398T3/da active
- 2017-02-06 ES ES17703965T patent/ES2877568T3/es active Active
- 2017-02-06 CN CN201780021480.1A patent/CN109071632B/zh active Active
- 2017-02-06 JP JP2018541289A patent/JP7166923B2/ja active Active
- 2017-02-06 US US16/075,317 patent/US11236166B2/en active Active
- 2017-02-06 CN CN202310792382.5A patent/CN116854826A/zh active Pending
- 2017-02-06 DK DK17703965.8T patent/DK3411065T3/da active
- 2017-02-06 JP JP2018541133A patent/JP7236273B2/ja active Active
- 2017-02-06 CA CA3013558A patent/CA3013558C/en active Active
- 2017-02-06 WO PCT/EP2017/052550 patent/WO2017134305A1/en not_active Ceased
- 2017-02-06 CN CN202211603239.9A patent/CN115850521A/zh active Pending
- 2017-02-06 CA CA3013551A patent/CA3013551A1/en active Pending
- 2017-02-06 EP EP17704697.6A patent/EP3411398B1/en active Active
- 2017-02-06 EP EP17704207.4A patent/EP3411397A1/en not_active Withdrawn
- 2017-02-06 CN CN202310792348.8A patent/CN116813799A/zh active Pending
- 2017-02-06 JP JP2018541357A patent/JP7030704B2/ja active Active
- 2017-02-06 JP JP2018540141A patent/JP6991979B2/ja active Active
- 2017-02-06 EP EP21165264.9A patent/EP3909978A1/en active Pending
- 2017-02-06 CN CN201780021559.4A patent/CN109071627B/zh active Active
- 2017-02-06 CA CA3013554A patent/CA3013554A1/en active Pending
- 2017-02-06 ES ES17705564T patent/ES2981745T3/es active Active
- 2017-02-06 CN CN201780021264.7A patent/CN109071663B/zh active Active
- 2017-02-06 US US16/075,312 patent/US10988538B2/en active Active
- 2017-02-06 CN CN201780021194.5A patent/CN108883180B/zh active Active
-
2020
- 2020-12-21 US US17/128,599 patent/US20210139586A1/en active Pending
-
2021
- 2021-04-05 US US17/222,043 patent/US12453770B2/en active Active
- 2021-12-17 US US17/554,180 patent/US12364753B2/en active Active
-
2022
- 2022-02-22 JP JP2022025686A patent/JP7386277B2/ja active Active
- 2022-07-08 JP JP2022110687A patent/JP2022153437A/ja active Pending
-
2024
- 2024-08-09 JP JP2024133824A patent/JP2024164840A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507135A5 (enExample) | ||
| JP2019507762A5 (enExample) | ||
| JP2019506867A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2019116474A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2019510478A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2020517239A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| IL253462B (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2017519759A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2018512175A5 (enExample) | ||
| JP2009506791A5 (enExample) | ||
| JP2017530691A5 (enExample) | ||
| JP2020533004A5 (enExample) | ||
| JP2021508707A5 (enExample) |